Cargando…

Selective Radionuclide Localisation in Primary Liver Tumours

The therapeutic potential of (131)I-Lipiodol was investigated in 8 patients with cholangiocarcinoma (CCA) and 15 patients with hepatocellullar carcinoma (HCC). Patients received one or two doses of (131)I-Lipiodol via hepatic arterial injection. The mean total administered activity was 668 (SD 325)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Novell, J. R., Green, A. J., Hilson, A. J. W., Dusheiko, G., Dick, R., Hobbs, K. E. F.
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 1994
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2423701/ https://www.ncbi.nlm.nih.gov/pubmed/8155585 http://dx.doi.org/10.1155/1994/93101

Ejemplares similares

Selective Regional Chemotherapy of Unresectable Hepatic Tumours Using Lipiodol
por: Novell, J. R., et al.
Publicado: (1991)

Histochemical Phosphatases and Metachromasia in Murine Tumours Induced by Bone Seeking Radionuclides
por: Bland, M. R., et al.
Publicado: (1974)

Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes
por: Stintzing, Sebastian, et al.
Publicado: (2017)

Dose conversion factors for intakes of selected radionuclides by infants and adults
por: Johnson, J R, et al.
Publicado: (1983)

Immunohistochemical localisation of tissue plasminogen activator in human brain tumours.
por: Franks, A. J., et al.
Publicado: (1989)

Iodinated hydroxyphenyl and hydroxynaphthyl porphyrins as tumour localisers.
por: Zanelli, G. D., et al.
Publicado: (1990)

Theranostics: radionuclide imaging and therapy in neuroendocrine tumours
por: Drake, Brent, et al.
Publicado: (2015)

Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour
por: da Silva, Tiago Nunes, et al.
Publicado: (2018)

The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody.
por: Pedley, R. B., et al.
Publicado: (1994)

Tumour localisation with a radioactively labelled reshaped human monoclonal antibody.
por: Hird, V., et al.
Publicado: (1991)

Production of selected cosmogenic radionuclides by muons; 1, Fast muons
por: Heisinger, B, et al.
Publicado: (2002)

A Case of Cerebellar Tumour, Considered with Reference to Its Localisation
por: Bruce, Alexander, et al.
Publicado: (1899)

In vitro assessment of Lipiodol-targeted radiotherapy for liver and colorectal cancer cell lines
por: Al-Mufti, R A M, et al.
Publicado: (1999)

Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors
por: Kucuk, Ozlem N, et al.
Publicado: (2011)

Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors
por: Kucuk, N Ozlem, et al.
Publicado: (2011)

In vivo fluorescence kinetics and localisation of aluminum phthalocyanine disulphonate in an autologous tumour model.
por: Witjes, M. J., et al.
Publicado: (1996)

Tumour-localising and -photosensitising properties of a novel zinc(II) octadecylphthalocyanine.
por: Ometto, C., et al.
Publicado: (1996)

Prolonged localisation of a monoclonal antibody against CEA in a human colon tumour xenograft.
por: Harwood, P. J., et al.
Publicado: (1985)

Cryosurgery: Its Role in Liver Tumours
por: Hobbs, K. E. F.
Publicado: (1993)

Salvage peptide receptor radionuclide therapy with [(177)Lu-DOTA,Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
por: van der Zwan, W. A., et al.
Publicado: (2018)

P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer.
por: Dahiya, R., et al.
Publicado: (1996)

Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade
por: Appleton, Elizabeth, et al.
Publicado: (2021)

Tumour localisation kinetics of photofrin and three synthetic porphyrinoids in an amelanotic melanoma of the hamster.
por: Leunig, M., et al.
Publicado: (1993)

Rolling out radioguided occult lesion localisation for breast tumours
por: Chung, David K V
Publicado: (2015)

Accuracy of semi-automated versus manual localisation of liver tumours in CT-guided ablation procedures
por: Boulkhrif, Hassan, et al.
Publicado: (2018)

Radionuclide Esophageal Transit Scintigraphy in Primary Hypothyroidism
por: Khan, Shoukat H, et al.
Publicado: (2017)

Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours
por: Hall, G H, et al.
Publicado: (2002)

The tumour-suppressive function of CLU is explained by its localisation and interaction with HSP60
por: Chaiwatanasirikul, K-A, et al.
Publicado: (2011)

The Localisation of Tumours of the Spinal Cord Amenable to Surgical Treatment
por: Paton, E. Percy
Publicado: (1896)

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Zaknun, John J., et al.
Publicado: (2013)

The Accuracy of Different Modalities Used for Preoperative Primary Tumour Localisation in Operated Colorectal Cancer Patients
por: Elnaggar, Mahmoud, et al.
Publicado: (2023)

The potential of carboxypeptidase G2: antibody conjugates as anti-tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model.
por: Melton, R. G., et al.
Publicado: (1990)

Radionuclides in the management of thyroid cancer
por: Buscombe, J.R.
Publicado: (2007)

Cellular localisation of tumour antigen (TA-4) in normal, dysplastic and neoplastic squamous epithelia of the upper aerodigestive tract.
por: Kearsley, J. H., et al.
Publicado: (1990)

Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Bodei, L., et al.
Publicado: (2013)

The distribution of porphyrins with different tumour localising ability among human plasma proteins.
por: Kongshaug, M., et al.
Publicado: (1989)

Endoplasmic reticulum and Golgi apparatus are the preferential sites of Foscan® localisation in cultured tumour cells
por: Teiten, M-H, et al.
Publicado: (2003)

Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours
por: Lim, Lisi Elizabeth, et al.
Publicado: (2020)

Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
por: Elston, Marianne S., et al.
Publicado: (2021)

Localisation of volatile isotopes on cryotraps
por: Neumayr, J.B, et al.
Publicado: (23/0)

Cannot write session to /tmp/vufind_sessions/sess_1fs9iirj6b1a0e55ifuccmm6dr